EP0585239A4 - Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication. - Google Patents

Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication.

Info

Publication number
EP0585239A4
EP0585239A4 EP19920906777 EP92906777A EP0585239A4 EP 0585239 A4 EP0585239 A4 EP 0585239A4 EP 19920906777 EP19920906777 EP 19920906777 EP 92906777 A EP92906777 A EP 92906777A EP 0585239 A4 EP0585239 A4 EP 0585239A4
Authority
EP
European Patent Office
Prior art keywords
absorbing
methods
making same
transparent appearance
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19920906777
Other languages
German (de)
English (en)
Other versions
EP0585239A1 (fr
EP0585239B1 (fr
Inventor
Kim Mitchell
Mark Mitchnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Smart Inc
Original Assignee
Sun Smart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0585239(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/651,696 external-priority patent/US5223250A/en
Application filed by Sun Smart Inc filed Critical Sun Smart Inc
Publication of EP0585239A4 publication Critical patent/EP0585239A4/fr
Publication of EP0585239A1 publication Critical patent/EP0585239A1/fr
Application granted granted Critical
Publication of EP0585239B1 publication Critical patent/EP0585239B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241Containing particulates characterized by their shape and/or structure
    • A61K8/025Explicitly spheroidal or spherical shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/445Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/26Optical properties
    • A61K2800/262Transparent; Translucent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/412Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the present invention relates generally to particulate materials adapted for use as sunblocking agents and more particularly to the use of these materials in transparent, cosmetically acceptable UV sunscreen products as well as in improved cosmetic formulations having an increased ability to protect the user from UV radiation.
  • One portion of the solar spectrum comprises wavelengths of electromagnetic energy which range between about 290 and 3,000 nanometers (n ) .
  • This range may be divided into different regions, namely: (1) the ultraviolet region (290-400nm) , (2) the visible region (400-760nm) and (3) the near-infrared region (>760nm) .
  • the ultraviolet region has, moreover, been arbitrarily divided into three bands, referred to as the UVA, UVB and UVC bands.
  • the UVB band extends from 290 to 320nm. It is the principal cause of the sunburn reaction and it is also the most effective in stimulating the tanning reaction in the skin.
  • UVC radiation 200-290nm
  • protection against UVC radiation is generally not a major concern, i.e., in contrast to the dangers posed by UVA and UVB radiation.
  • the UVA band which extends from 320-400nm, can also cause the tanning reaction. UVA radiation can also cause sunburns, but its capacity to do so is less than that of UVB radiation.
  • UVA radiation exposure is increasing. This is due to the fact that most sunscreens effectively block only UVB radiation.
  • UVB radiation is more capable than UVA radiation of causing the tanning and burning reactions. Therefore, if one is using a sunscreen that blocks UVB radiation he/she will tend to stay in the sun for an extended period of time because the immediate effects of the sun tan/burn are not evident.
  • the problem is that UVA is still penetrating the skin and although it is not causing any immediately obvious effects, it is causing long term damage. In recent years, it has been well documented that UVA radiation, like UVB radiation, is harmful to the skin.
  • UVA radiation has been shown to promote skin cancer by inhibiting enzymes that repair cells damaged by UVB radiation. UVA radiation also penetrates more deeply into the skin than UVB radiation and causes changes in blood vessels and premature aging of the skin, thus adding to the damage produced by UVB rays (see, e.g., Hurwitz, Sidney, "The Sun and Sunscreen Protection: Recommendations for Children", Dermatol. Sur ⁇ . Oncol; 14:6 (June 1988) p. 657) .
  • Sunscreen products can be grouped into two broad categories, i.e., (1) topical sunscreens and (2) oral sunscreens.
  • the present invention focuses upon the topical sunscreens, which can be further differentiated into two subcategories, namely (1) chemical sunscreens and (2) physical sunscreens.
  • Chemical sunscreens contain from about 3 to about 26% of one or more UV-absorbing chemicals. When applied to 5 the surface of the skin as a thin film, i.e., about 10-15 ⁇ m in thickness, these chemicals act as a filter to diminish the penetration of UV radiation to the cells of the epidermis. These sunscreens are typically applied in a cream, oil, lotion, alcohol or gel vehicle and they are 0 usually colorless because they do not contain any visible light-absorbing chemicals.
  • the most widely used chemical sunscreens contain, for example, para-aminobenzoic acid (PABA) , PABA esters (glyceryl PABA, amyldimethyl PABA and octyldi ethyl PABA) , benzophenones (oxybenzone and
  • Physical sunscreens comprise particles of a relatively physiologically inert sunblock, i.e., UV-absorbing, compound typically suspended in a cream or lotion.
  • Materials frequently utilized for this purpose include kaolin, talc and two metal oxides, i.e., titanium dioxide and zinc oxide. The latter two compounds are not associated with the inflammatory reactions noted above.
  • the physical sunscreen products are, however, typically messy and occlusive. Moreover, they additionally form a visible, colored (e.g., white) layer on the surface of the skin which is cosmetically unacceptable to many who are in need of sunscreen protection. This causes many such individuals to forego the use of these products.
  • the color of these compositions is attributable to the optical properties of the particles from which these materials are formed. These properties are at least partially dependent upon the size of these particles, which typically have a fairly "standard" range of diameters, measured in tenths of a micron (i.e., greater than about 0.7-0.9 ⁇ ).
  • certain commercial sunscreen products containing titanium dioxide are made with what is known as “micronized” or “large surface area” particles of the metal oxide. It should be noted here that the term “micronized” does not denote a specific particle size. Rather, the term is only used to describe small particles having a large surface area.
  • the titanium dioxide particles utilized in these sunblock products have a diameter an order of magnitude smaller (i.e., measuring about O.Ol ⁇ ) than the "standard" sized particles (measuring greater than about 0.7-0.9 ⁇ ) described above.
  • titanium dioxide absorbs neither as much UV-radiation nor transmits as much visible radiation as, for example, zinc oxide, which is utilized by applicants in the present invention (see, e.g., Brown, Harvey E. , Zinc Oxide: Properties and Applications, pp. 11-12, Fig. 2-4 (1976)).
  • this material i.e., its comparatively lower effectiveness (in contrast to ZnO) as a sunblock agent.
  • Titanium dioxide-based products are also more opaque than those formed with the zinc oxide of the present invention, which is due to the fact that the crystalline structure of the titanium dioxide material renders it only partially transparent to visible wavelengths of light and thus not generally as acceptable for cosmetic use.
  • micronized particles of zinc oxide for very specialized uses in the rubber industry, these particles contain substantial quantities (i.e., greater than about 200 ppm) of trace metals such as lead, mercury, arsenic and cadmium.
  • trace metals such as lead, mercury, arsenic and cadmium.
  • the potential dangers to human health caused by exposure to these materials is we11-documented.
  • zinc oxide particles containing these levels of trace metals are not acceptable for topical application to human skin.
  • the invention is directed to a sunscreen formulation comprising micronized particles of a zinc oxide sunblock suspended in a der atologically suitable liquid carrier, preferably in the form of an emulsion.
  • micronized zinc oxide particles for use with the present invention measure up to about 0.2 ⁇ in size.
  • These micronized particles are formed using known techniques, such that the resultant particles have acceptable, i.e., reduced, levels of trace metals such as cadmium, arsenic, mercury, lead, etc. , which levels are set forth in Table I below. These levels are substantially lower than those found in the particles described above for use in the rubber industry where toxicity is not a concern.
  • Applicants' particles, having the requisite levels of these trace metals for use in the present invention are therefore referred to in the present specification as substantially "pure”.
  • This substantially “pure” material is thus suitable for application to human skin since the trace metal content is maintained at or below the levels se t forth in Table I below, that is, below levels which are likely to cause dangerous effects in humans.
  • Zinc oxide particles of the size and morphology described herein, with such reduced levels of trace metal contamination, have not been previously known in the art, as far as applicants are aware. There has, in fact, been no call for this substantially pure form of zinc oxide since, as described herein, the use of this visually transparent UV-sunblock material was not previously contemplated by those working in the sunscreen or the cosmetic fields.
  • substantially pure zinc oxide particles are formed having a substantially spherical shape. This shape is preferred because it provides a smooth "feel" on the skin of the user. A variety of other crystalline shapes, such as needles, rhomboids, etc. have also been found to provide acceptable UV protection, however, and may be utilized in the formulations of the invention as well, although as noted above, spherical particles are the most preferred.
  • sunscreen products formed with this material remain visibly transparent on the skin while absorbing a greater portion of the UVA and UVB radiation than was previously possible with the use of prior art sunblock compositions, without resulting in any adverse effects caused due to transdermal absorption. This result is not possible with the only other commonly used metal oxide, i.e., titanium dioxide, due to the different, i.e., less effective, optical properties exhibited by titanium dioxide.
  • a second embodiment of the present invention is directed to the formation of physical sunscreen products comprising a particulate zinc oxide sunblock, preferably spherical in shape, having a diameter of an order of magnitude greater than the "standard size" (i.e., greater than about 0.7-0.9 ⁇ ) particles used in prior art sunscreen compositions described above.
  • the particles used in the subject embodiment are thus also substantially larger than the micronized particles described for use with the previous embodiment, i.e., they measure at least about 1 micron, and preferably between about 1-100 microns in diameter. At diameters above about lOO ⁇ , the optical performance of this material appears to deteriorate somewhat.
  • these particles be prepared by a process, such as gas phase chemical vapor deposition (CVD) , spray pyrolysis or sol-gel particle formation, which results in the formation of symmetrical, substantially “optically perfect" crystals which are essentially free of internal fractures and/or other physical imperfections, and which have a relatively smooth outer surface.
  • CVD gas phase chemical vapor deposition
  • Such crystals as a result of their morphology, have the required optical properties for use with the sunscreen formulations of the present invention, i.e., they absorb a substantial portion of the ultraviolet radiation to which, they are exposed, which, as noted above, is greater than that which is absorbed with the use of prior art sunblock products, while remaining transparent in the range of visible wavelengths.
  • the relatively large crystals of the subject embodiment are also substantially pure as described above and thus contain only insignificant amounts of the trace metals listed in Table I below.
  • the "purity" of these particles renders sunscreen formulations containing this sunblock material suitable for topical application to human skin without danger due to transdermal absorption of trace metals.
  • the substantially pure zinc oxide particles are incorporated into a liquid carrier, such as the emulsion described above, to form a visibly transparent sunscreen formulation capable of absorbing a substantial portion, if not all, of the ultraviolet radiation directed upon the skin of the user to which this material is applied.
  • particles of a visibly transparent UV-absorbing glass may be substituted within the emulsion for the zinc oxide particles described above.
  • the glass particles used in the subject embodiment have an average diameter ranging between about 0.01 - 100 microns. They must also possess a relatively smooth outer surface and be substantially free of internal fractures or other physical imperfections.
  • One well-known optical glass composition which has been shown to provide the desired results is referred to as Corning BK-7 (i.e., borosilicate crown-7) glass. The formulation of this material is well known and thus need not be described herein.
  • a still further embodiment of the present invention comprises a physical sunscreen formed with a plurality of small, visibly clear plastic spheres measuring between about 0.01-100 microns in diameter.
  • one or more UV absorbing compounds which may be chosen from a variety of materials well known in the art, are incorporated into the plastic used to form these spheres.
  • the UV absorbing compound once incorporated into the plastic spheres, can no longer react with or be absorbed by the skin.
  • These UV absorbent spheres are then dispersed in a liquid vehicle, such as the emulsion discussed above, to form a visibly transparent sunscreen lotion which may be topically applied to prevent ultraviolet radiation from reaching the skin of the user.
  • the particulate materials described above for use in the sunscreen formulations of the present invention may also be incorporated by known blending methods into a variety of cosmetic products such as lipstick, eyeshadow, foundations, moisturizer, rouge and the like to form cosmetics having an increased ability to prevent damage to underlying skin by the action of solar UV radiation.
  • this parameter is defined by a characteristic optical energy known as the "bandgap" energy.
  • Semiconductor materials such as the metal oxides, the visibly transparent glasses (e.g., BK-7) and UV-absorbing plastics described herein are transparent to wavelengths above this bandgap value while they absorb energy having a wavelength lower than the bandgap energy.
  • materials whose bandgap energies are such that they remain visibly transparent while absorbing wavelengths of light below about 400 nm, i.e., in the ultraviolet range.
  • Optical reflection and refraction are the remaining properties which must be taken into account in predicting the performance of the particulate materials chosen for use in the present invention.
  • the ability of a particle to reflect light is affected by the morphology of the surface of the material of which the particle is formed, by the angle of light incident to the surface of the material and by the difference in the index r b- of refraction of the material compared to that of the surrounding media. That is, the closer the refractive index of the particulate material is to that of the medium in which it is suspended, the less visible contrast there will be.
  • Formulation bases for use on human skin typically Q have a refractive index of no greater than about 1.6 while the refractive index of titanium dioxide is about 2.5 and that of zinc oxide is about 1.9. This difference makes it possible for zinc oxide to more readily blend with a suitable base while not significantly contributing to that 5 mixture's visible optical properties.
  • particles i.e., crystals, formed with rough surf ces or having internal fractures or other physical imperfections will scatter incident light more than smooth particles and/or those lacking such fractures 0 and imperfections. It is thus preferred to use particles having a substantially smooth outer surface which are relatively free of internal fractures and imperfections in the present invention. This enables sunscreen products formed with these sunblock materials to absorb a 5 substantial portion of the UV wavelengths to which the user is exposed while remaining substantially transparent on the surface of the skin.
  • the substantially pure zinc oxide of applicants' invention i.e., having a minimal trace metal content as 0 set forth in Table I below, is preferred for use herein in order to take advantage of the abrupt transition which zinc oxide undergoes from reflector to absorber at a bandgap energy corresponding to a wavelength of about 385 nm, i.e.,
  • a further advantage to the use of zinc oxide over titanium dioxide in the sunblock formulations of the present invention is that zinc oxide is substantially less expensive than titanium dioxide, thus providing a significant cost savings with the use of this material in applicants' invention. Still further, as noted above, applicants' substantially pure micronized zinc oxide particles contain a substantially lower amount of trace metals than is typically found in the specialty purpose micronized particles of this material. The use of such prior art micronized zinc oxide is, as discussed above, not possible because of the toxicity of this material due to the relatively high concentrations of trace metals contained therein.
  • these zinc oxide particles are preferably spherical in shape to provide a "smooth" feel to the product and to facilitate its application onto the skin, but non-spherical particles, such as needles, squares, rhomboids, etc., may also serve the required purpose, although they are not as preferred.
  • micronized particles of zinc oxide are known in the art for specialty applications in the rubber industry, such particles contain elevated levels, i.e. greater than 200 ppm, of toxic trace metal contaminants. These trace metals include lead, cadmium, mercury and arsenic, all of which are known to be hazardous to human health.
  • trace metals include lead, cadmium, mercury and arsenic, all of which are known to be hazardous to human health.
  • the "substantially pure" zinc oxide particles developed by applicants for use in the present invention whether in the form of micronized particles or as larger, “optically perfect” particles as described above, contain no more than the following ranges of the trace metals listed below:
  • Suitable carriers for forming the emulsion described above include SD alcohol, lanolin, glyceryl stearate, cocoa butter, sorbitan sesquioleate, propylene glycol, mineral oil, isopropyl myristate, petrolatum and acrylic polymers. Mixtures of two or more of these materials may also be used. These materials are known in the art as being "dermatologically suitable", i.e., they do not cause or promote adverse reactions upon the skin of the user.
  • the amount of the carrier need only be sufficient to provide a uniform dispersion of the particles when they are applied to the skin to ensure adequate coverage of the skin with the UV absorbing material.
  • the particulate material preferably comprises no more than about 20% by weight of the total emulsion and preferably between about 1-10% by weight thereof. The only real limit on the lower end of this concentration range is that a sufficient quantity of the particulate must be included to permit the formulation to absorb the desired amount of UV light. Concentrations of less than about 1% by weight of the total composition may even be useful in some instances.
  • a second embodiment of the applicants' sunblock formulations comprises substantially pure particles of zinc oxide, preferably spherical in shape, having a diameter substantially greater by at least an order of magnitude than the "standard" sized zinc oxide particles used with prior art sunscreen compositions described above and about two orders of magnitude greater than the micronized zinc oxide particles.
  • the zinc oxide particles preferred for use in the subject embodiment of the invention measure at least about 1 micron in diameter, and preferably between about 5-20 microns. The upper end of this range is not critical, however and thus the subject particles may range up to 50 or even 100 microns in diameter.
  • the particles need not be spherical, although that shape is preferred since it facilitates application of the sunblock composition onto the skin when the zinc oxide particles are dispersed in a liquid carrier such as the emulsion discussed above.
  • concentration of these particles within the emulsion is essentially the same as that used for the embodiment utilizing micronized zinc oxide, i.e., between about 1-20% by weight and preferably between about 1-10% by weight.
  • the bandgap energy value of zinc oxide is such that it changes from transparent to opaque at approximately the border between visible and UV light.
  • the substantially pure zinc oxide particles of the subject embodiment are preferably formed with the use of a chemical vapor deposition ("CVD") technique, which results in the formation of symmetrical particles of zinc oxide having a diameter within the range noted above, which appear visibly clear upon the surface of the skin while remaining capable of absorbing a substantial portion of the UV radiation to which they are exposed.
  • CVD chemical vapor deposition
  • zinc source compositions are introduced as vapors into a heated reaction volume, i.e., chamber, where they react with oxygen, typically supplied as a gas, to form the zinc oxide particles described above, i.e., ranging in size from about 1 to about 100 microns.
  • the driving force for this reaction can be the exothermic formation energy of the zinc oxide product itself or this energy may instead be supplied by external sources such as thermal or radio frequency (RF) plasma energy.
  • RF radio frequency
  • the CVD process utilized by applicants may utilize, as a zinc source, compositions such as zinc acetate, zinc chloride, zinc oxalate or organometallic zinc compounds such as dimethyl zinc (“DMZ”) and dimethyl zinc (“DEZ”) .
  • DMZ dimethyl zinc
  • DEZ dimethyl zinc
  • Applicants have determined that zinc oxide formed with the use of CVD from an organometallic zinc source will achieve particles having high growth rates at relatively low growth temperatures, i.e., below 500°C and are thus preferred.
  • the zinc sources used are thus preferably DMZ and DEZ, whereas the oxidizing gas may be selected from among gaseous water, oxygen and alcohol.
  • both DEZ and DMZ are liquids, they are contained, prior to use, in a conventional bubbler device, typically maintained at about 20°C, whereupon they are subsequently transferred to the reactor via a carrier gas such as nitrogen or argon which is bubbled through the liquid. Water vapor is introduced to the reactor in a similar manner.
  • the zinc and oxidizer source chemicals are injected into the hot reaction chamber through separate nozzles where they mix and react to form the zinc oxide particles.
  • the ratio of oxidizing gas to the organometallic zinc should be greater than about 7:1, preferably about 10:1, in order to completely oxidize the zinc.
  • the reaction temperature may range from about 180 to about 500°C, with the preferred range being from about 300 to 400°C.
  • the reaction pressure can range from 1 torr to about 760 torr. For purposes of simplifying the apparatus, however, atmospheric pressure is preferred.
  • the desired zinc oxide particle size is achieved by (1) manipulating the amount of reactants used by, for example, a mass flow-controller, and (2) the residence time of these materials in the reactor. The relationship between these parameters is such that, for example, increasing the amount of time the reactants spend in the reaction chamber will result in a proportional size increase in the zinc oxide particles thus formed.
  • the resultant substantially pure zinc oxide particles having a diameter ranging in size from about 1-100 microns, are formed with a substantially smooth outer surface and, in addition, are substantially free of internal fractures and/or other physical imperfections.
  • an antireflection coating of, for example, silicon oxide may be applied to the surface of these particles to reduce the optical reflection from the material/media interfaces which thus renders them even more transparent to visible light.
  • acceptable zinc oxide particles may be formed with the use of other conventional processes such as spray pyrolysis (see, e.g., Eberspacher et al., "Pyrolysis of ZnO Film Deposited Onto InP By Spray Pyrolysis," Thin Solid Films, 136 (1986, pp. 1-10) or sol-gel particle formation, both of which are well known to those skilled in the art.
  • particles of a visibly transparent glass having a bandgap energy at about 400nm, thus permitting it to absorb UV light while remaining virtually transparent to visible light may be dispersed in the carrier in place of the 1- lOO ⁇ zinc oxide particles described above.
  • the diameter of the glass particles preferred for use in the invention may range between about 0.01-100 microns.
  • these glass particles must have a substantially smooth outer surface and be substantially free of internal fractures and other imperfections. Any such optical glass meeting the requirements set forth above may be utilized, although borosilicate glasses such as the visibly transparent Corning BK-7 material described above are preferred for use with the present invention.
  • the antireflective coatings described above may also be used to coat the optically active glass particles of the type described herein.
  • a sunscreen lotion including a plurality of commercially available plastic particles preferably, although not necessarily, spherical in shape with a diameter ranging between about 0.01-100 ⁇ , formed, in part, of a visibly transparent plastic.
  • plastics are well-known in the art and may include, for example, acrylics such as polymethyl ethacrylate (“PMMA”) ; styrene polymers; copolymers of styrene and acrylic; styrene acrylonitrile (“SAN”) ; polycarbonate; methylpentene; terpolymers of acrylonitrile, butadiene and styrene (“ABS”) and allyl diglycol carbonate (“ADC”) .
  • PMMA polymethyl ethacrylate
  • ABS terpolymers of acrylonitrile, butadiene and styrene
  • ADC allyl diglycol carbonate
  • any visibly transparent plastic having, or capable of being modified to have, as described below, the desired optical properties to render it visibly transparent but capable of absorbing UV radiation is suitable for use in the present invention.
  • one or more UV absorption additives also known as "UV stabilizers” may be incorporated into the plastic used to produce the spheres during their formation.
  • UV stabilizers may be incorporated into the plastic used to produce the spheres during their formation.
  • UV additives are well known in the art (see, e.g., Modern Plastic Encyclopedia 1976-1977, pp. 222-227 and 708-709 and U.S. patent No. 4,882,143 to Kadokura et al., col. 7 lines 61-65) and include materials such as derivatives of salicylic acid, benzoic acid, cinnamic acid and benzophenone, benzotriazoles, aryl esters, substituted acrylonitrile, metallic complexes and inorganic pigments.
  • the invention should not be limited to the use of these specific materials, however, since any UV additive which serves the intended purpose, i.e., absorbing ultraviolet radiation, can be used with the formulations described with regard to the subject embodiment of the invention.
  • the inclusion of these additive materials into the plastic spheres described above serves to render these visibly transparent spheres capable of absorbing UV radiation.
  • a liquid carrier such as the emulsion described with reference to the embodiment of the invention utilizing substantially pure particles of micronized zinc oxide, in a concentration ranging between about 1-20% by weight of the emulsion and, more preferably, between about 1-10% by weight
  • the resultant formulation may be topically applied onto the skin of the user, whereupon it remains visibly transparent while absorbing a substantial portion of the UV radiation to which the user is exposed.
  • the particulate sunblock materials described above for inclusion in the topical sunscreen formulations of the present invention may, in still further embodiments of the invention, be incorporated into a variety of cosmetic products such as, for example, lipstick, eyeshadow, foundations, moisturizers, rouge and other personal care products to enhance the ability of these formulations to protect the underlying skin of the user from the damaging effects of UV radiation.
  • cosmetic products such as, for example, lipstick, eyeshadow, foundations, moisturizers, rouge and other personal care products to enhance the ability of these formulations to protect the underlying skin of the user from the damaging effects of UV radiation.
  • These materials may be blended with the cosmetic base by known blending methods such as by means of Henschel mixer, a ribbon mixer, a twin-cylinder mixer or the like.
  • the amount of such particulate material present within the cosmetic formulations of the invention comprises no more than about 20% by weight, and preferably between about 1-10% by weight. Most preferably, the particulate sunblock agent comprises less than 1% by weight of the total formulation.
  • the cosmetic formulations described above may also contain a variety of additive materials. These additives are well-known in the art and are added for the purpose of performing their inherent functions.
  • the preferred additives include materials such as thickeners, softeners, superfatting agents, waterproofing agents, emollients, wetting agents and surface-active agents, as well as preservatives, anti-foam agents, perfumes and mixture thereof, or any other compatible ingredient usually employed in cosmetics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Prostheses (AREA)
EP92906777A 1991-02-05 1992-02-04 Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication Revoked EP0585239B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/651,696 US5223250A (en) 1991-02-05 1991-02-05 Visibly transparent UV sunblock cosmetic compositions
US651696 1991-02-05
US70425091A 1991-05-22 1991-05-22
US704250 1991-05-22
PCT/US1992/000860 WO1992013517A1 (fr) 1991-02-05 1992-02-04 Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication

Publications (3)

Publication Number Publication Date
EP0585239A4 true EP0585239A4 (fr) 1993-12-06
EP0585239A1 EP0585239A1 (fr) 1994-03-09
EP0585239B1 EP0585239B1 (fr) 1998-09-23

Family

ID=27096129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92906777A Revoked EP0585239B1 (fr) 1991-02-05 1992-02-04 Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication

Country Status (6)

Country Link
US (1) US5587148C1 (fr)
EP (1) EP0585239B1 (fr)
JP (1) JPH06509321A (fr)
AU (1) AU668862B2 (fr)
DE (1) DE69227109T2 (fr)
WO (1) WO1992013517A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585239B1 (fr) 1991-02-05 1998-09-23 Sun Smart, Inc. Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication
GB9121143D0 (en) * 1991-10-04 1991-11-13 Tioxide Chemicals Limited Dispersions
GB9121153D0 (en) * 1991-10-04 1991-11-13 Tioxide Chemicals Ltd Method of preparing sunscreens
US5441726A (en) * 1993-04-28 1995-08-15 Sunsmart, Inc. Topical ultra-violet radiation protectants
GB9403451D0 (en) * 1994-02-23 1994-04-13 Ciba Geigy Ag Sunscreen compositions
AU734334B2 (en) * 1994-04-22 2001-06-14 Submicro Encapsulation Technologies, Inc. Composite UV sunblock compositions
DE59509732D1 (de) * 1994-05-04 2001-11-29 Spirig Pharma Ag Egerkingen Lichtschutzmittel
FR2736543B1 (fr) * 1995-07-13 1997-08-29 Oreal Compositions cosmetiques anhydres contenant des nanopigments de ti02 et des microspheres creuses deformables
GB9616978D0 (en) * 1996-08-13 1996-09-25 Tioxide Specialties Ltd Zinc oxide dispersions
AUPO688997A0 (en) 1997-05-20 1997-06-12 Soltec Research Pty Ltd Sunscreen composition
US5972359A (en) * 1997-05-23 1999-10-26 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
EP1167462B1 (fr) * 1999-01-11 2010-12-22 Showa Denko K.K. Preparation cosmetique, particules d'oxyde metallique enrobees d'un sol de silice rendues hydrophobes en surface, oxyde metallique revetu de sol de silice rendues hydrophobes et procedes de production
US6261694B1 (en) 1999-03-17 2001-07-17 General Electric Company Infrared reflecting coatings
US6420032B1 (en) 1999-03-17 2002-07-16 General Electric Company Adhesion layer for metal oxide UV filters
US6517687B1 (en) 1999-03-17 2003-02-11 General Electric Company Ultraviolet filters with enhanced weatherability and method of making
US6365016B1 (en) 1999-03-17 2002-04-02 General Electric Company Method and apparatus for arc plasma deposition with evaporation of reagents
US6426125B1 (en) 1999-03-17 2002-07-30 General Electric Company Multilayer article and method of making by ARC plasma deposition
US6627178B1 (en) 1999-07-30 2003-09-30 Garret D. Cawthon Methods, compositions and systems for the prevention and treatment of diaper rash
US6500415B2 (en) 2000-06-05 2002-12-31 Showa Denko K.K. Cosmetic composition
US6555075B2 (en) 2001-05-23 2003-04-29 Raymond Lee Nip Method of preparing zinc carbonate
AUPS080802A0 (en) * 2002-02-27 2002-03-21 Advanced Powder Technology Pty Ltd A zinc oxide powder for use in a sunscreen composition
EP1508599A1 (fr) * 2003-08-22 2005-02-23 Degussa AG Oxyde de zinc traitée en surface
US20050147571A1 (en) * 2003-11-05 2005-07-07 Loyd Dennis D. Ultraviolet absorption
US20050281852A1 (en) * 2003-11-05 2005-12-22 Tri E Holding, Llc Zinc calcium aluminum phosphate
DE10357683A1 (de) * 2003-12-10 2005-07-07 Goldschmidt Ag UV-Absorber enthaltende Autopflegemittel
US7695726B2 (en) * 2004-01-23 2010-04-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Pigmented cosmetic composition exhibiting radiance with soft focus
KR20070011394A (ko) * 2004-03-23 2007-01-24 더 클로록스 캄파니 차아염소산염의 희석법
US20050249684A1 (en) * 2004-05-07 2005-11-10 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Taurate formulated pigmented cosmetic composition exhibiting radiance with soft focus
GB0517043D0 (en) 2005-08-19 2005-09-28 York Pharma Plc Improvements in pharmaceutical compositions
US20110150792A1 (en) * 2008-12-10 2011-06-23 Yun Shao Zinc oxide aqueous and non-aqueous dispersions
US20080206156A1 (en) * 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US8021649B2 (en) 2007-02-22 2011-09-20 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US20090117162A1 (en) * 2007-11-01 2009-05-07 Victor Bruce H Topical Cosmetic Compositions
US20090155371A1 (en) 2007-12-17 2009-06-18 Sojka Milan F Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same
US8632816B2 (en) 2007-12-17 2014-01-21 Elc Management, Llc Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same
IL206909A0 (en) 2008-01-11 2010-12-30 Antaria Ltd Mesoporous zinc oxide powder and method for production thereof
US20100119465A1 (en) * 2008-06-13 2010-05-13 Playtex Products, Llc Enhanced photoactivity of semiconductors
AU2009258149B2 (en) * 2008-06-13 2012-12-13 Edgewell Personal Care Brands, Llc Enhanced photoconductivity and SPF of semiconductors
US8119698B2 (en) * 2008-06-30 2012-02-21 Conopco, Inc. Sunscreen formula vanishing cream
DE102008035236A1 (de) * 2008-07-29 2010-02-04 Dyckerhoff Ag Betontrennmittel
BRPI0914084A2 (pt) * 2008-10-07 2015-10-27 Union Carbide Chem Plastic composição para cuidado dos cabelos e método para prevenir o descoramento dos cabelos
JP2012532133A (ja) 2009-06-30 2012-12-13 ダウ グローバル テクノロジーズ エルエルシー 日焼け防止剤含有可溶性フィルム
US20110044920A1 (en) * 2009-08-07 2011-02-24 Mary Kay Inc. Topical skin care formulations
WO2011038120A1 (fr) * 2009-09-25 2011-03-31 Pharmasol Corporation Revêtements de surface pour la peau
JP5815554B2 (ja) * 2009-12-16 2015-11-17 ダウ グローバル テクノロジーズ エルエルシー メチルセルロースをspfおよび/またはppdの上昇剤として組入れるサンスクリーン組成物ならびに方法
JP2013517270A (ja) 2010-01-19 2013-05-16 イーエルシー マネージメント エルエルシー 複合微粒子、組成物および方法
EP2542341A2 (fr) 2010-03-05 2013-01-09 Basf Se Sels de zinc modifiés de diacides alcane en c4-8 et leur utilisation comme catalyseur de polymérisation
US8430053B2 (en) 2010-09-30 2013-04-30 Temptime Corporation Color-changing emulsions for freeze indicators
JP6039646B2 (ja) 2011-03-31 2016-12-07 ローム アンド ハース カンパニーRohm And Haas Company サンケア組成物、及び方法
WO2012173696A2 (fr) 2011-04-21 2012-12-20 Playtex Products, Llc. Photoactivité améliorée de semi-conducteurs et/ou de produits de protection solaire
KR101993359B1 (ko) 2011-04-27 2019-06-26 아이에스피 인베스트먼츠 엘엘씨 투명 습윤 스프레이 및 젤
US20140377197A1 (en) 2011-12-22 2014-12-25 Dow Global Technologies Llc Suncare formulations and methods
US9717679B1 (en) 2012-12-17 2017-08-01 Touchless Designs LLC Methods for the prevention and treatment of animal skin conditions
DE102017119863A1 (de) * 2017-08-30 2019-02-28 Jürgen Lademann Kosmetisches Licht- und Sonnenschutzmittel
DE112018004752T5 (de) 2017-09-05 2020-06-10 Vizor, Llc Mit einem hydroxycinnamat- und silanol-addukt beschichtete anorganische sonnenschutzmittel
DE112018004877T5 (de) 2017-09-05 2020-06-18 Vizor, Llc Anorganische sonnenschutzmittel mit höherem uv-strahlungsschutz

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4756672A (en) * 1972-10-15 1974-04-26 John Cornwell Wright Robert Sunscreening preparation
JPS5798205A (en) * 1980-12-09 1982-06-18 Pola Chem Ind Inc Cosmetic giving durable make-up
JPS60184004A (ja) * 1984-03-02 1985-09-19 Pola Chem Ind Inc 化粧料
JPS60231607A (ja) * 1984-04-28 1985-11-18 Kobayashi Kooc:Kk 日焼け止め化粧料
GB2184356A (en) * 1985-12-18 1987-06-24 Kao Corp Anti-suntan cosmetic composition
FR2622441A1 (fr) * 1987-10-28 1989-05-05 Oreal Composition cosmetique transparente reflechissant le rayonnement infrarouge et son utilisation pour la protection de l'epiderme humain contre le rayonnement infrarouge
FR2646346A1 (fr) * 1989-04-26 1990-11-02 Thorel Jean Composition pour le depot topique d'un film continu permeable et reflechissant la lumiere

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2175213A (en) * 1937-06-15 1939-10-10 Henry C Parker Composition for preventing sunburn
US3226297A (en) * 1954-03-31 1965-12-28 Bofors Ab Dentifrice compositions comprising polymethyl methacrylate abrasives
US3258844A (en) * 1964-03-27 1966-07-05 Warren L Godman Dividing device
FR1486277A (fr) * 1965-07-09 1967-10-05
US3574822A (en) * 1966-07-26 1971-04-13 Nat Patent Dev Corp Powdered cosmetics of hydrophilic hydroxy lower alkyl acrylates and methocrylates
US3441579A (en) * 1967-06-16 1969-04-29 Toyo Koatsu Ind Inc Organic imino compound metal halide complexes and process for producing the same
US4172122A (en) * 1977-07-29 1979-10-23 Minnesota Mining And Manufacturing Company Substantive sunscreening compositions
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4349536A (en) * 1980-03-11 1982-09-14 Hausler Kenneth J Method of promoting suntan using a cream containing zinc and copper salts
US4486405A (en) * 1983-04-19 1984-12-04 William H. Rorer, Inc. Pigmented cosmetic vehicle containing a mixture of alkoxylated surfactants
LU85304A1 (fr) * 1984-04-13 1985-11-27 Oreal Composition solaire filtrante contenant du polyisobutylene et son utilisation pour la protection de l'epiderme humain contre les radiations ultraviolettes
LU85746A1 (fr) * 1985-01-28 1986-08-04 Oreal Composition cosmetique filtrante contenant un filtre uv associe a un polymere obtenu par polymerisation sequentielle en emulsion et son utilisation pour la protection de l'epiderme humain contre les radiations ultraviolettes
US4828825A (en) * 1986-09-15 1989-05-09 University Of Miami Infrared reflecting composition for topical application to the skin
JP2591946B2 (ja) * 1986-11-17 1997-03-19 住友化学工業株式会社 薄片状金属化合物及びこれを配合してなる化粧料
US4822600A (en) * 1987-05-27 1989-04-18 Neutrogena Corporation Infrared blocker
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5028417A (en) * 1987-07-20 1991-07-02 Johnson & Johnson Consumer Products, Inc. Sunscreen compositions
US4861651A (en) * 1988-06-02 1989-08-29 Goldenhersh Michael A Ultraviolet blocking material and method of making same
DE3838094A1 (de) * 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
US4917882A (en) * 1989-03-16 1990-04-17 Amway Corporation Gel-type sunscreen composition
JPH03279323A (ja) * 1989-12-15 1991-12-10 Johnson & Johnson Consumer Prod Inc 日焼け止め組成物
EP0585239B1 (fr) 1991-02-05 1998-09-23 Sun Smart, Inc. Agents antisolaires absorbant les uv et d'aspect transparent et leurs procedes de fabrication

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4756672A (en) * 1972-10-15 1974-04-26 John Cornwell Wright Robert Sunscreening preparation
JPS5798205A (en) * 1980-12-09 1982-06-18 Pola Chem Ind Inc Cosmetic giving durable make-up
JPS60184004A (ja) * 1984-03-02 1985-09-19 Pola Chem Ind Inc 化粧料
JPS60231607A (ja) * 1984-04-28 1985-11-18 Kobayashi Kooc:Kk 日焼け止め化粧料
GB2184356A (en) * 1985-12-18 1987-06-24 Kao Corp Anti-suntan cosmetic composition
FR2622441A1 (fr) * 1987-10-28 1989-05-05 Oreal Composition cosmetique transparente reflechissant le rayonnement infrarouge et son utilisation pour la protection de l'epiderme humain contre le rayonnement infrarouge
FR2646346A1 (fr) * 1989-04-26 1990-11-02 Thorel Jean Composition pour le depot topique d'un film continu permeable et reflechissant la lumiere

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8230, Derwent World Patents Index; AN 82-62269 *
DATABASE WPI Week 8544, Derwent World Patents Index; AN 85-272732 *
PATENT ABSTRACTS OF JAPAN vol. 10, no. 98 (C - 339)<2155> *

Also Published As

Publication number Publication date
WO1992013517A1 (fr) 1992-08-20
DE69227109D1 (de) 1998-10-29
JPH06509321A (ja) 1994-10-20
DE69227109T2 (de) 1999-02-18
US5587148C1 (en) 2001-11-20
EP0585239A1 (fr) 1994-03-09
AU1565692A (en) 1992-09-07
US5587148A (en) 1996-12-24
AU668862B2 (en) 1996-05-23
EP0585239B1 (fr) 1998-09-23

Similar Documents

Publication Publication Date Title
EP0585239A4 (fr) Agents antisolaires absorbant les uv et d&#39;aspect transparent et leurs procedes de fabrication.
DE59400352D1 (de) Einkaufswagen
DE69424027D1 (de) Katheter
NO944047D0 (no) Strömningsledet kateter
DE69429670D1 (de) Verbesserter ballonkatheter
DE69433410T2 (de) Dilatationskatheter
DE69311847D1 (de) Ballonkatheter
DE69423046D1 (de) Schnellzurückziehbarer katheter
IT1245604B (it) Differenziale
FR2712801B1 (fr) Structure absorbante et vêtement l&#39;incorporant.
BR9406092A (pt) Cateter
ITMI910685A0 (it) Differenziale
KR950702293A (ko) 차동장치
KR920005118U (ko) 어린이 글자 교습 놀이구
KR940025409U (ko) 어린이용 습자 연습 글자판
KR930020981U (ko) 때밀이구
FI930590A7 (fi) Pienen lapsen keinu
ES1020080Y (es) Muneco infantil
KR930022878U (ko) 가구의 고저수평 조절구
KR930000672U (ko) 어린이용 노상썰매
KR920000378U (ko) 어린이용 놀이기구
ES1025466Y (es) &#34;bolsa absorbente&#34;
KR920002751U (ko) 아동용 풀장
ES1022029Y (es) &#34;mueble convertible infantil&#34;
ES1020268Y (es) Columpio infantil.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930805

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19950406

TPAD Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOS TIPA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

REF Corresponds to:

Ref document number: 69227109

Country of ref document: DE

Date of ref document: 19981029

ET Fr: translation filed
PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAV Examination of admissibility of opposition

Free format text: ORIGINAL CODE: EPIDOS OPEX

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

26 Opposition filed

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

26 Opposition filed

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: HAARMANN & REIMER GMBH

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

26 Opposition filed

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: HAARMANN & REIMER GMBH

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

RDAH Patent revoked

Free format text: ORIGINAL CODE: EPIDOS REVO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

APAE Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOS REFNO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: HAARMANN & REIMER GMBH

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: SYMRISE GMBH & CO. KG

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

PLAQ Examination of admissibility of opposition: information related to despatch of communication + time limit deleted

Free format text: ORIGINAL CODE: EPIDOSDOPE2

PLAR Examination of admissibility of opposition: information related to receipt of reply deleted

Free format text: ORIGINAL CODE: EPIDOSDOPE4

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: SYMRISE GMBH & CO. KG

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070205

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070330

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070209

Year of fee payment: 16

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080204

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20081031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080229

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLAU Termination of opposition procedure: information related to despatch of decision deleted

Free format text: ORIGINAL CODE: EPIDOSDOPC1

PLBD Termination of opposition procedure: decision despatched

Free format text: ORIGINAL CODE: EPIDOSNOPC1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080204

RDAD Information modified related to despatch of communication that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSCREV1

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: SYMRISE GMBH & CO. KG

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: KAZUMI IMAMURA

Effective date: 19990623

Opponent name: SACHTLEBEN CHEMIE GMBH

Effective date: 19990623

Opponent name: SAKAI CHEMICAL INDUSTRY CO LTD

Effective date: 19990623

Opponent name: ELEMENTIS UK LIMITED

Effective date: 19990621

Opponent name: SYMRISE GMBH & CO. KG

Effective date: 19990621

Opponent name: IMPERIAL CHEMICAL INDUSTRIES PLC, THE MANAGER, INT

Effective date: 19990616

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

27W Patent revoked

Effective date: 20091020